The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
Open Access
- 20 June 2019
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (3) , 774-783
Abstract
Cell identity relies on the cross-talk between genetics and epigenetics and their impact on gene expression. Oxidation of 5-methylcytosine into 5-hydroxymethylcytosine is the first step of an active DNA demethylation process occurring mainly at enhancers and gene bodies and, as such, participates in processes governing cell identity in normal and pathological conditions. Although genetic alterations are well documented in multiple myeloma, epigenetic alterations associated with this disease have not yet been thoroughly analyzed. To gain insight into the biology of multiple myeloma, genome-wide 5-hydroxymethylcytosine profiles were obtained and showed that regions enriched in this modified base overlap with multiple myeloma enhancers and super enhancers and are close to highly expressed genes. Through the definition of a multiple myeloma-specific 5-hydroxymethylcytosine signature, we identified FAM72D as a poor prognostic gene located on 1q21, a region amplified in high risk myeloma. We further uncovered that FAM72D functions as part of the FOXM1 transcription factor network controlling cell proliferation and survival and evidenced an increased sensitivity of cells expressing high levels of FOXM1 and FAM72 to epigenetic drugs targeting histone deacetylases and DNA methyltransferases.Keywords
This publication has 52 references indexed in Scilit:
- Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancersNucleic Acids Research, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- CENTDIST: discovery of co-associated factors by motif distributionNucleic Acids Research, 2011
- Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosineNature Biotechnology, 2011
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- Ugene, a Newly Identified Protein That Is Commonly Overexpressed in Cancer and Binds Uracil DNA GlycosylaseCancer Research, 2008
- IRF4 addiction in multiple myelomaNature, 2008
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2British Journal of Haematology, 2008
- The molecular classification of multiple myelomaBlood, 2006
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationBlood, 2006